Influenza virus resistance to antiviral agents: a plea for rational use - PubMed (original) (raw)

Influenza virus resistance to antiviral agents: a plea for rational use

Gregory A Poland et al. Clin Infect Dis. 2009.

Abstract

Although influenza vaccine can prevent influenza virus infection, the only therapeutic options to treat influenza virus infection are antiviral agents. At the current time, nearly all influenza A/H3N2 viruses and a percentage of influenza A/H1N1 viruses are adamantane resistant, which leaves only neuraminidase inhibitors available for treatment of infection with these viruses. In December 2008, the Centers for Disease Control and Prevention released new data demonstrating that a high percentage of circulating influenza A/H1N1 viruses are now resistant to oseltamivir. In addition, oseltamivir-resistant influenza B and A/H5N1 viruses have been identified. Thus, use of monotherapy for influenza virus infection is irrational and may contribute to mutational pressure for further selection of antiviral-resistant strains. History has demonstrated that monotherapy for influenza virus infection leads to resistance, resulting in the use of a new monotherapy agent followed by resistance to that new agent and thus resulting in a background of viruses resistant to both drugs. We argue that combination antiviral therapy, new guidelines for indications for treatment, point-of-care diagnostic testing, and a universal influenza vaccination recommendation are critical to protecting the population against influenza virus and to preserving the benefits of antiviral agents.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. G.A.P. serves as an investigator for vaccine clinical studies funded by Wyeth; serves as the chair of a safety evaluation committee for a novel influenza vaccine and other vaccines being developed by Merck Research Laboratories; offers consultative advice on new vaccine development to Glaxo-SmithKline, Merck, Novartis, Novavax, Avianix, CSL Limited, Discovery Institute of America, Emergent BioSolutions, Information Television Network, Haymarket Medical, and Spaldataq; and is an advocacy group board member for Families Fighting Flu. R.M.J. serves as an investigator for vaccine clinical studies funded by Wyeth and serves on a safety review committee for a postlicensure study of Gardasil for Kaiser-Permanente. I.G.O.: no conflicts.

Similar articles

Cited by

References

    1. Bright RA, Medina MJ, Xu X, et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet. 2005;366:1175–81. - PubMed
    1. Gubareva LV, Kaiser L, Hayden FG. Influenza virus neuraminidase inhibitors. Lancet. 2000;355:827–35. - PubMed
    1. Hay A. Amantadine and rimantadine—mechanisms. In: Richman DD, editor. Antiviral drug resistance. Chichester, United Kingdom: John Wiley & Sons; 1996. pp. 43–58.
    1. Hayden FG, Hay AJ. Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr Top Microbiol Immunol. 1992;176:119–30. - PubMed
    1. Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI. Adamantane resistance among influenza A viruses isolated early during the 2005–2006 influenza season in the United States. JAMA. 2006;295:891–4. - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources